Viracta Therapeutics
Stock Forecast, Prediction & Price Target
Viracta Therapeutics Financial Estimates
Viracta Therapeutics Revenue Estimates
Viracta Therapeutics EBITDA Estimates
Viracta Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $3.5M Low: $3.5M High: $3.5M avg. 0% | Avg: $30.32M Low: $30.32M High: $30.32M avg. 766.34% | Avg: $39.72M Low: $39.72M High: $39.72M avg. 31.00% | Avg: $94.19M Low: $94.19M High: $94.19M avg. 137.12% |
Net Income
% change YoY
| $-203.06M N/A | $-49.77M 75.48% | $-51.05M -2.57% | Avg: $-89.18M Low: $-48.66M High: $-40.55M avg. -74.66% | Avg: $-88.39M Low: $-59.48M High: $-35.14M avg. 0.88% | Avg: $-43.77M Low: $-43.77M High: $-43.77M avg. 50.47% | Avg: $-33.02M Low: $-33.02M High: $-33.02M avg. 24.55% |
EBITDA
% change YoY
| $62.68M N/A | $-50.58M -180.70% | $-46.86M 7.36% | Avg: $699.99K Low: $699.99K High: $699.99K avg. 101.49% | Avg: $6.06M Low: $6.06M High: $6.06M avg. 766.34% | Avg: $7.94M Low: $7.94M High: $7.94M avg. 31.00% | Avg: $18.83M Low: $18.83M High: $18.83M avg. 137.12% |
EPS
% change YoY
| -$6.37 N/A | -$1.32 79.27% | -$1.32 0% | Avg: -$1.16 Low: -$1.26 High: -$1.05 avg. 12.50% | Avg: -$1.23 Low: -$1.54 High: -$0.91 avg. -6.06% | Avg: -$1.13 Low: -$1.13 High: -$1.13 avg. 7.48% | Avg: -$0.86 Low: -$0.86 High: -$0.86 avg. 24.55% |
Operating Expenses
% change YoY
| $25.79M N/A | $50.58M 96.09% | $50.69M 0.20% | Avg: $36.65M Low: $36.65M High: $36.65M avg. -27.68% | Avg: $317.56M Low: $317.56M High: $317.56M avg. 766.34% | Avg: $416.01M Low: $416.01M High: $416.01M avg. 31.00% | Avg: $986.50M Low: $986.50M High: $986.50M avg. 137.12% |
FAQ
What is Viracta Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 0.31% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -48.66M, average is -89.18M and high is -40.55M.
What is Viracta Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 233.61% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $3.5M, average is $3.5M and high is $3.5M.
What is Viracta Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 9.62% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$1.26, average is -$1.16 and high is $-1.05.